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Abstract 
 
B-cell lymphomas often develop in the central nervous system (CNS). Although rituximab (RTX) has 
been widely used for most B-cell lymphomas, the efficacy for CNS lymphomas has yet to be elucidated. 
A major concern is that RTX might not reach lymphoma lesions, and either the antibody-dependent 
cellular cytotoxicity or complement-dependent cytotoxicity (CDC) might not substantially operate in the 
CNS environment. Here we investigated the potential usefulness of co-administering RTX and human 
serum intraventricularly in nude rats carrying human B-cell lymphomas in the CNS. Raji, a 
CD20-positive lymphoma cell line, was inoculated into the cerebrum of F344 (rnu/rnu) nude rats. After 
several days, RTX and human serum were delivered into the ipsilateral lateral ventricle via a cannula. 
Intraventricularly administered RTX was localized specifically at the lymphoma lesions, indicating that 
RTX penetrated the ependymal layer of the lateral ventricle to reach the tumor lesion, where it 
specifically bound to the lymphoma cells. The combination of RTX and serum (n = 12), but not RTX 
alone (n = 13), significantly extended the survival of the rats (P=0.049). Intraventricular administration of 
RTX and serum in a rat/human CNS lymphoma model might be a potential novel treatment for CNS 
lymphomas of B-cell origin. Clinical trials are warranted. 
 
Keywords: CNS lymphoma, rituximab, complement-dependent cytotoxicity, intraventricular
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1 Introduction 
 
Central nervous system (CNS) involvement is one of the serious manifestations of B-cell 
lymphomas. It occurs as extranodal involvement of systemic lymphoma, often during relapse, or as a 
primary CNS lymphoma, which is now termed “primary diffuse large B-cell lymphoma (DLBCL) of the 
CNS” in version 4 of the WHO classification [1]. High-dose methotrexate with or without radiotherapy 
is the current mainstay of treatment. However, side effects, such as severe cytopenia, renal insufficiency, 
and delayed neurological damage are a concern, especially in heavily pretreated or elderly patients. Even 
if these therapies are initially effective, long-term outcomes remain poor [2-4]. 
Rituximab (RTX) is a monoclonal antibody against CD20, a four-transmembrane protein 
whose expression is confined to precursor and mature B cells [5, 6]. RTX, which consists of the variable 
region of mouse antibody and the constant region of human IgG1 [7], is widely used to treat systemic 
B-cell lymphomas. RTX is considered to have its therapeutic effect through (i) antibody-dependent 
cell-mediated cytotoxicity (ADCC), mainly mediated by natural killer cells [8-10]; (ii) 
complement-dependent cytotoxicity (CDC) mediated by complement factors that are activated by 
binding of the complement protein C1q to RTX [8, 10-14]; and (iii) induction of tumor cell apoptosis by 
CD20 stimulation [15-17]. Despite the fact that intravenous RTX is effective against most B-cell 
lymphomas, its efficacy against B-cell lymphomas developing in the CNS (hereafter designated CNSL) 
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has not yet been shown. The presence of the blood–brain barrier might hamper intravenous RTX from 
reaching the CNSL, given that the concentration of RTX in the cerebrospinal fluid (CSF) is 1% or less 
of that in the blood when it is administered intravenously [18-20].  
CSF is produced at the choroid plexus in the lateral ventricle, flows through the third and 
fourth ventricle, and finally flows into the subarachnoid space. CSF also spreads from the lateral 
ventricle into the brain parenchyma through ependymal cells, which form a thin epithelial membrane 
lining the cerebral ventricle [21]. Some cytokines and antibodies administered into the lateral ventricle 
do penetrate into the brain parenchyma [21-24]. In addition, the pia mater, which directly covers the 
brain surface, is also a leaky structure [21]. Therefore, intrathecal or intraventricular administration of 
RTX could be a viable choice of treatment for CNSL. However, another important concern about the 
potential effectiveness of RTX against CNSL is that the CNS environment lacks immune cells and 
complement, the two key factors needed for RTX to kill the target cells. 
To investigate whether RTX can be used to treat CNSL, we developed a human CNSL 
xenograft model in rats and evaluated the efficacy of intraventricular co-administration of RTX and 
human serum. 
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2 Materials and methods 
 
2.1 Antibodies and serum 
RTX was kindly supplied by Zenyaku Kogyo Co. Ltd (Tokyo, Japan). Human polyclonal 
immunoglobulin (Gammagard
®
, Baxter, Deerfield, IL) was used as a control immunoglobulin for RTX. 
Human serum was separated from the clotted whole blood of a healthy volunteer by centrifugation at 
1600 × g and stored at –30°C. Inactivated serum was prepared by placing the human serum at 56°C for 
30 minutes. 
  
2.2 Cell line and cell culture 
Raji, a CD20-positive human Burkitt lymphoma cell line, was obtained from RIKEN 
BioResource Center (Tsukuba, Japan) and was cultured in RPMI1640 medium (Sigma-Aldrich, St. 
Louis, MO) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and penicillin and 
streptomycin (Sigma-Aldrich; used at 100 units/mL and 100 μg/mL, respectively) at 37°C with 10% 
CO2 in humidified air. 
 
2.3 Complement-dependent cytotoxicity assay 
Raji cells (1.0 × 10
5) were cultured in medium containing 20 μg/mL RTX and various 
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concentrations of human serum in 96-well round-bottom dishes for 7 hours. After the incubation, 50 μL 
of propidium iodide (PI; 7.5 μg/mL) was added and analyzed by flow cytometry (FACSCalibur®, Becton 
Dickinson, Franklin Lakes, NJ). The ratio of PI-positive dead cells to all analyzed cells was measured to 
evaluate complement-dependent cytotoxicity.  
 
2.4 CNSL model rats 
Eight-week old F344 (rnu/rnu)  nude rats were purchased from CLEA Japan (Tokyo, Japan) 
and were bred in Laboratory Animal Resource Center, University of Tsukuba. Experiments with rats 
described in this paper were approved by Laboratory Animal Resource Center, University of Tsukuba. 
The nude rats were anesthetized with pentobarbital (Dainippon Sumitomo Pharma, Osaka, 
Japan) and immobilized with a brain stereotaxic apparatus. To create a port to administer RTX and 
serum, a 23-gauge stainless steel tube with a removable internal stopper was cannulated into the 
ipsilateral lateral ventricle at 1.6 mm lateral and 0.8 mm caudal to bregma, and fixed at a 4.5 mm depth 
from the cranial bone surface. The cannula was secured to the cranial surface with dental resin cement. 
Proper cannulation was confirmed in brain sections from rats sacrificed immediately after the 
administration of trypan blue through the cannula (n = 2). While the cannulation was performed, 
exponentially growing Raji cells were harvested at a density of 1  106 to 1.5  106 cells/mL and washed 
once in phosphate-buffered saline without calcium and magnesium (PBS). After the cells were 
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centrifuged and the supernatant was removed, the cell pellet was loosened by tapping, aspirated into a 
microinjector, and left on ice until inoculation. A 5-μL aliquot of this pellet, which contained 1  106 to 3 
 106 cells, was inoculated into the deep frontal lobe of the cerebrum of the above-prepared nude rats at 
2 mm lateral and 3 mm rostral to bregma, and 4.5 mm deep to the cranial bone surface.  
 
2.5 Immunohistochemical analysis 
From days 9 to 11 after Raji cell inoculation, 100 μg RTX or control immunoglobulin in 10 μL 
of 0.154 M NaCl solution (saline) was administered with 10 μL human serum once a day into the lateral 
ventricle through the cannula. The animals were euthanized and the brains were surgically removed 24 
hours after the last administration, embedded in OCT compound (Sakura Finetechnical, Tokyo, Japan), 
frozen at –80°C, sliced at 3 or 6 μm with a cryostat, and immunohistologically analyzed following a 
standard protocol. In brief, after blocking nonspecific adhesion with BPT solution (1% bovine serum 
albumin [Sigma-Aldrich], PBS, and 0.1% Tween 20 [Sigma-Aldrich]), the sections were incubated with 
antibody in BPT solution. To confirm the presence of the Raji-cell tumor in the brain, the sections were 
stained with RTX and Fluorescein isothiocyanate (FITC)-conjugated rabbit anti-human IgG 
immunoglobulin or control FITC-conjugated rabbit immunoglobulin (DAKO, Glostrup, Denmark).  
 To evaluate whether intraventricular RTX reached the tumor cells, consecutive sections were 
directly stained with FITC-conjugated rabbit anti-human IgG immunoglobulin or control 
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FITC-conjugated rabbit immunoglobulin. Rats administered control immunoglobulin and human serum 
were stained in the same manner as negative controls. After rinses, the samples were covered with 
VECTASHIELD Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA) and observed 
with an Axioplan2 fluorescent microscope (Carl Zeiss, Oberkochen, Germany). Images were taken and 
analyzed with an AxioCam CCD camera and AxioVision4.6 image processing software (Carl Zeiss), 
respectively.  
 
2.6 Treatment of lymphomas in CNSL model rats 
 
Once a day on day 5 through day 9 after Raji innoculation, CNSL model rats were 
intraventricularly administered with a mixture of 100 μg (10 μL) of RTX or control immunoglobulin 
with 10 μL of human serum, or a mixture of the same dose of RTX with saline. The survival data were 
collected from 10 independent experiments. The rats were observed and weighted once a day after 
intraventricular administration. When >25% weight reduction or obvious weakness was observed, the rat 
was euthanized, and this time point was defined as the end of survival. The brains were removed from 
all of the rats, regardless of whether death was natural or by euthanasia. If no lymphoma was found in 
the brain, the animal was excluded from the analysis. Survival of each group was analyzed with the 
Kaplan-Meier method and log-rank test with StatCell version 2 software (OMS, Saitama, Japan), and 
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significant differences were assumed at P values <0.05. 
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3 Results 
 
We first analyzed the induction of CDC by RTX and human serum in vitro using cells of the 
CD20-positive human non-Hodgkin lymphoma B-cell line Raji as a target. Cytotoxicity was observed 
with the combination of RTX and serum, but not with the combinations of control immunoglobulin and 
serum or of RTX and heat-inactivated serum (Fig. 1). To investigate the efficacy of intraventricular RTX 
combined with serum, we generated a rat CNSL model in which Raji cells were inoculated into the deep 
white matter of the nude rat brain frontal lobe (Fig. 2). Tumor formation was confirmed histologically in 
brains removed 12 days after inoculation (Fig. 3). At the time of Raji cell inoculation, an indwelling 
cannula was implanted into the lateral ventricle on the ipsilateral side to use as the route of 
intraventricular administration (Fig. 2). Most rats recovered fully after the operation and those which did 
not recovered were excluded from the following experiments. Next, the rats were administered with 
RTX or control immunoglobulin and human serum via the cannula for three consecutive days beginning 
on day 9 after Raji inoculation. Rats recovered normally after general anesthesia and intraventricular 
administration of the study drugs. Twenty-four hours after the last administration, the brains were 
removed for analysis by immunostaining. We observed specific staining with an FITC-conjugated rabbit 
anti-human immunoglobulin (Fig. 4, upper panels), but not with a control FITC-conjugated rabbit 
immunoglobulin (middle panels); this staining was present only after the administration of RTX (Fig. 4, 
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Exp. 1 and Exp. 2) and not after control human immunoglobulin [Fig. 4, Exp. 1 (control) and Exp. 2 
(control). Note that control immunoglobulin was not detected even in the high sensitivity with some 
background in Exp. 1 (control) and Exp. 2 (control)]. The staining area largely overlapped with the 
CD20-positive Raji cell tumor area (Fig. 4, lower panels). This demonstrates that intraventricular RTX 
penetrated the ependymal layer and brain parenchyma, and finally reached and bound to lymphoma cells. 
To evaluate the anti-lymphoma effect of intraventricular RTX and serum, the tumor-inoculated rats were 
treated with either RTX plus serum, RTX plus saline, or control immunoglobulin plus serum. 
Lymphoma development was confirmed histologically in all the rats examined. A single rat in the 
RTX-plus-serum group died from technical error during the treatment period and was excluded from this 
analysis. The RTX-plus-serum group survived significantly longer than the 
control-immunoglobulin-plus-serum group (P = 0.049; Fig. 5). The RTX-plus-serum group also 
appeared to survive longer than the RTX-plus-saline group, although the difference was not statistically 
significant (P = 0.083). The survival times of the RTX-plus-saline and 
control-immunoglobulin-plus-serum groups did not differ from each other (P = 0.382). Body weights 
transiently decreased immediately after the intraventricular treatment in all arms, but all the rats 
subsequently re-gained the weight, which began to decrease shortly before the death (Supplemental Fig. 
1). 
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Discussion 
 
A few rodent CNSL models have been described previously in which lymphoma cells were 
directly inoculated into deep cerebral white matter [25, 26]. On the basis of the information in these 
articles, we established a CNSL model in nude rats bearing a tumor made from the Raji cell line, which 
is widely used for CDC and ADCC assays with RTX in vitro [8, 10, 12] and in vivo [27, 28]. An 
intracerebral Raji cell tumor established in athymic mice was recently reported to recapitulate the 
histopathology and molecular features of primary CNSL [29]. Although the authors of that paper 
emphasized that their model was suitable for preclinical testing of novel agents, mice are too small and 
technically difficult to handle for many investigators. We therefore chose a nude rat as a host. 
 In this paper, we showed that intraventricular RTX reaches the tumor through the ependymal 
layer and brain parenchyma, although the fluorescence intensity of tumor-bound RTX was much weaker 
than the positive control staining (Fig. 4). This indicates that only a fraction of RTX penetrated the brain 
parenchyma, although the dilution associated with diffusion in the brain might also be attributed. 
 Despite the low concentration of RTX into the tumor, our results indicate that the binding of 
RTX to the Raji cell tumor induced tumor killing. Because this effect was dependent on human serum, it 
is likely that the cell killing was actually due to CDC against the Raji tumor cells in vivo. It is also 
possible that RTX and complement induced tumor cell phagocytosis by microglial cells, which are 
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known to possess Fc and complement receptors [30, 31]. In addition, other effector cells such as 
monocytes and NK cells might also migrate to the tumor site after the initial CDC or phagocytosis. 
The relatively modest effect of intraventricular RTX and serum (Fig. 5) could be due to an insufficient 
dose of RTX at the tumor, given the low level of RTX binding to the tumor cells. Increasing the 
concentration of intraventricular RTX might therefore improve the efficacy in clinical settings. 
Alternatively, although clinical studies should be more complicated, directly administering monocytes or 
NK cells may be more advantageous to elicit continuous anti-lymphoma effect in the CNS. 
Intrathecal or intraventricular RTX, administered as a single agent, has been reported to be 
effective against CNS lymphomas in clinical settings. The efficacy, however, has mainly been described 
for leptomeningeal involvement of B-cell lymphomas rather than the lesions in the brain parenchyma 
[20, 32, 33]. These reports are largely consistent with our findings that the survival times of the 
RTX-plus-saline and control-immunoglobulin-plus-serum groups did not differ from each other (Fig. 5).  
Recently, a case of refractory primary CNSL that was treated with intraventricular RTX and 
autologous serum was reported [34]. The patient’s condition initially deteriorated, but remarkable tumor 
regression occurred after 8 weeks. Our results provide experimental evidence in support of this clinical 
report. The authors of the clinical report discussed the possible induction of an adaptive immune 
response to explain the relatively slow clinical course, rather than the immediate effect expected from 
CDC. Because dendritic cells have been shown to emerge in the CNS in mouse CNS inflammation 
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models [35], it is possible that, after CDC, CNSL-associated antigens were processed and presented on 
brain dendritic cells and adaptive immunity was initiated, leading to tumor regression. 
Our treatment model could be adapted for use in patients because intraventricular cannulation 
and Ommaya reservoir implantation are routinely performed by neurosurgeons. Given the possible slow 
effect, intraventricular RTX and autoserum treatment might be suitable as a consolidation or 
maintenance therapy for CNSL in clinical settings. Clinical trials are warranted. 
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Fig. 1 
 
 
Complement-dependent cytotoxicity of rituximab and serum. 
Complement-dependent cytotoxicity of Raji cells treated with the indicated concentrations of 
human serum in the presence of rituximab or control human immunoglobulin (cont Ig) was measured. 
Inact-serum, heat-inactivated serum. Data are representative of two independent experiments.  
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Fig. 2 
 
 
Positions of intracerebral inoculation of Raji cells and intraventricular cannulation. 
Raji cells were inoculated into the deep frontal lobe. The cannula was placed in the ipsilateral 
lateral ventricle. 
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Fig. 3 
 
Histological study of rat cerebrum after Raji cell inoculation. 
A coronal section of nude rat cerebrum was stained with hematoxylin and eosin 12 days after 
Raji cell inoculation. Left panel: macroscopic finding. The Raji cell tumor is depicted by basophilic 
staining in the right hemisphere. Right panel: histology in a high-power field (400). Raji cells diffusely 
infiltrated in the deep frontal lobe of the cerebrum. The scale bar indicates 1 mm.  
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Fig. 4 
 
Figure 4
Specific binding of rituximab to tumor cells in the cerebrum after intraventricular administration.  
Rituximab plus serum (Exp. 1 and Exp. 2) or control immunoglobulin plus serum [Exp. 1 
(control) and Exp. 2 (control)] was administered into the lateral ventricles of the rats from day 9 to day 11 
after Raji cell inoculation. The animals were euthanized, and the brains were surgically removed and 
stained 24 hours after the last administration. Sections were stained with FITC-conjugated anti-human 
IgG (Anti-hIgG, upper panels) or FITC-conjugated control immunoglobulin (middle panels). To clarify 
the margin of the Raji cell tumor, the section was stained with rituximab as the primary antibody and 
FITC-conjugated anti-human IgG as a secondary antibody (lower panels). DAPI (4', 
6-diamidino-2-phenylindole) was used for nuclear staining. The yellow box depicts the area of the Raji 
cell infiltration and the scale bar indicates 500 μm. Data are representative of three independent 
experiments. 
 
Fig. 5 
 
 
 
Therapeutic effect of intraventricular administration of rituximab and serum. 
Kaplan-Meier survival curves. Data were collected from 10 pooled experiments. The rats were 
treated with rituximab plus serum (Rituximab + Serum, n = 12), rituximab plus saline (Rituximab + saline, 
n = 13), or control immunoglobulin plus serum (Cont Ig + Serum, n = 13). The asterisk indicates a 
statistically significant difference between rituximab plus serum and control immunoglobulin plus serum 
(P = 0.049) in a log-rank test. 
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